Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine (HDP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00956943
Recruitment Status : Completed
First Posted : August 11, 2009
Results First Posted : March 18, 2013
Last Update Posted : August 15, 2014
Information provided by (Responsible Party):
Robert Schnoll, University of Pennsylvania

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: Triple (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Nicotine Dependence
Interventions: Drug: Nicoderm CQ transdermal nicotine
Drug: placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Media ads asked treatment-seeking smokers to call for information about a smoking cessation program and to have their initial eligibility reviewed. Participants interested in the clinical trial and initially eligible attended an in-person session to determine their final eligibility. Recruitment was from 2009-2011.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
To be eligible, participants had to be: between age 18 and 55, smoke >10 cigarettes/day, and able to communicate in English. In addition, participants had to have a 3-HC/cotinine ratio that placed them in the top 3 quartiles of the 3-HC/cotinine ratio distribution to be consider fast nicotine metabolizers, which was >.18.

Reporting Groups
21mg Transdermal Nicotine + Placebo Patch

21mg transdermal nicotine + placebo patch

Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks

placebo : placebo patch

42mg Transdermal Nicotine

42mg transdermal nicotine

Nicoderm CQ transdermal nicotine : Transdermal nicotine patch (21mg vs. 42mg), 8 weeks

Participant Flow:   Overall Study
    21mg Transdermal Nicotine + Placebo Patch   42mg Transdermal Nicotine
STARTED   43   44 
Baseline   43   44 
COMPLETED   34   34 
Lost to Follow-up                9                10 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
21mg Transdermal Nicotine + Placebo Patch No text entered.
42mg Transdermal Nicotine No text entered.
Total Total of all reporting groups

Baseline Measures
   21mg Transdermal Nicotine + Placebo Patch   42mg Transdermal Nicotine   Total 
Overall Participants Analyzed 
[Units: Participants]
 43   44   87 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   43   44   87 
>=65 years   0   0   0 
[Units: Years]
Mean (Standard Deviation)
 37.1  (9.0)   38.8  (9.0)   38  (9) 
[Units: Participants]
Female   22   23   45 
Male   21   21   42 
Region of Enrollment 
[Units: Participants]
United States   43   44   87 

  Outcome Measures

1.  Primary:   Biochemically Verified 7-day Point Prevalence Abstinence at the End of 8 Weeks of Treatment   [ Time Frame: After 8 weeks of treatment with the patch, outcome will be measured. ]

2.  Secondary:   Side Effects   [ Time Frame: 8 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
This was a proof of concept trial and, as such, was inadequately powered to detect statistically significant treatment arm effects and did not include a long-term follow-up assessment.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Robert A. Schnoll, Ph.D.
Organization: University of Pennsylvania
phone: 215-746-7143

Responsible Party: Robert Schnoll, University of Pennsylvania Identifier: NCT00956943     History of Changes
Other Study ID Numbers: 809716
R21DA026889 ( U.S. NIH Grant/Contract )
First Submitted: July 23, 2009
First Posted: August 11, 2009
Results First Submitted: January 14, 2013
Results First Posted: March 18, 2013
Last Update Posted: August 15, 2014